The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyle Markel
• Treatments: Ticagrelor

Criteria

Inclusion Criteria:

• Peripheral arterial disease

• Planned angioplasty or stenting of superficial femoral artery or popliteal artery.

Exclusion Criteria:

• Patients treated on an emergency basis

• Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty)

• Planned intervention at site exclusive of superficial femoral artery or popliteal artery

• Planned re-stenting at site of prior stent placement

• Planned re-angioplasty at site of prior angioplasty

• Known inability to tolerate antiplatelet regimen before enrollment

• Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center

• Current use of prasugrel or ticlopidine

• Current use of oral anticoagulation medication

• Pregnant patients